respiratory syncytial virus

News

GSK's RSV shot cleared in US for all adults

GSK is back on level pegging with its rivals in the RSV vaccine category in the US, after getting FDA approval for Arexvy in the 18 to 49 age bracket.

News

UK body raps Sanofi for disparaging Pfizer's RSV jab

Sanofi been found to be in breach of the UK pharma industry's code of practice over an article in which it compared its RSV jab to a Pfizer rival.

News

CHMP decision levels the playing field for GSK's RSV jab

GSK's RSV vaccine is poised for EU approval in all adults aged 18 and over, bringing it into line with rival shots from Pfizer and Moderna.

News

Are RSV shots next in line for restrictions in the US?

After pushing for restrictions on vaccines for COVID-19 and hepatitis B, the Trump administration seems to be turning its attention to RSV shots.

News

Enanta weakens on RSV treatment trial readout

Shares in Enanta Pharma were sliding this morning after it reported results of a phase 2b trial of its RSV antiviral zelicapavir.

News

Stéphane Bancel, Moderna's chief executive

Moderna's RSV shot gets US nod for use in younger adults

The label for Moderna's RSV vaccine mResvia has been expanded to include adults aged 18 and over in the US, but will that lead to an uptick in sales?

GSK's RSV shot cleared in US for all adults

UK body raps Sanofi for disparaging Pfizer's RSV jab

CHMP decision levels the playing field for GSK's RSV jab

Are RSV shots next in line for restrictions in the US?

Enanta weakens on RSV treatment trial readout

Moderna's RSV shot gets US nod for use in younger adults

After setback, Rhythm gets good news on Imcivree from FDA

Using AI-driven synthetic personas to take your insights fur...

respiratory syncytial virus

Editor's Picks